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Abstract. Background: MAP/microtubule affinity-regulating kinase 4 (MARK4) is a serine-threonine kinase expressed in two
spliced isoforms, MARK4L and MARK4S, of which MARK4L is a candidate for a role in neoplastic transformation.
Methods: We performed mutation analysis to identify sequence alterations possibly affecting MARK4 expression. We then
investigated the MARK4L and MARK4S expression profile in 21 glioma cell lines and 36 tissues of different malignancy grades,
glioblastoma-derived cancer stem cells (GBM CSCs) and mouse neural stem cells (NSCs) by real-time PCR, immunoblotting
and immunohistochemistry. We also analyzed the sub-cellular localisation of MARK4 isoforms in glioma and normal cell lines
by immunofluorescence.
Results: Mutation analysis rules out sequence variations as the cause of the altered MARK4 expression in glioma. Expression
profiling confirms that MARK4L is the predominant isoform, whereas MARK4S levels are significantly decreased in comparison
and show an inverse correlation with tumour grade. A high MARK4L/MARK4S ratio also characterizes undifferentiated cells,
such as GBM CSCs and NSCs. Accordingly, only MARK4L is expressed in brain neurogenic regions. Moreover, while both
MARK4 isoforms are localised to the centrosome and midbody in glioma and normal cells, the L isoform exhibits an additional
nucleolar localisation in tumour cells.
Conclusions: The observed switch towards MARK4L suggests that the balance between the MARK4 isoforms is carefully
guarded during neural differentiation but may be subverted in gliomagenesis. Moreover, the MARK4L nucleolar localisation in
tumour cells features this MARK4 isoform as a nucleolus-associated tumour marker.
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1. Introduction
The MAP/microtubule affinity-regulating kinase
(MARK) proteins, a family of serine-threonine kinases
related to PAR-1 (partitioning-defective 1) [1, 2],
first became known for their ability to phosphory-
late microtubule-associated proteins (MAPs), leading
to the destabilization of microtubules [3, 4]. Among
the wide range of functions ascribed to MARKs, roles
in cell polarity, cell cycle control and cell signalling
have been frequently examined [3–8]. All members
of the MARK family (MARK1-4) [9] share a nearly
identical protein structure, which includes the kinase-
associated domain 1 (KA1) or a similar domain at
the C terminus, and are regulated by multiple path-
ways acting through different mechanisms [10]. The
function of the KA1 domain is still unknown, but an
autoinhibitory function and/or interaction with pro-
teins binding to the tail region have been shown in
Saccharomyces and proposed as novel strategies for
the regulation of MARKs and related kinases [7]. The
MARK4 human paralogue encodes two splice variants,
namely L and S. The alternative splicing of exon 16,
which causes a frameshift and creates a downstream
stop codon, accounts for the difference between the
carboxy-terminal ends of MARK4L and S. MARK4L
contains the KA1 motif, whereas MARK4S has a
unique domain with no homology with any known pro-
tein structure [11, 12], suggesting that the two isoforms
have different functions. In keeping with this notion,
the two MARK4 isoforms have been reported to have
different expression patterns. MARK4S was found to
be up-regulated in mouse neurons after induced focal
ischemia [13], and it appeared to be predominantly
expressed in normal brain tissue and in mature and dif-
ferentiated neurons [12]. Conversely, MARK4L was
up-regulated in hepatocarcinoma cell lines [11] and
highly expressed in primary glioma cell lines and neu-
ral progenitor cells, suggesting involvement in cellular
proliferation [14]. This also applies to MARK3, which
has been found mutated in two colorectal tumours [15],
and MARK1, which is down-regulated in primary gas-
tric cancers [16] and up-regulated in lung carcinoma
[17]. By using a full chromosome 19 coverage array,
we have shown that MARK4 gene is not amplified
in glioma [18], although it resides within a region
of gain at the centromeric boundary of the 19q13.3
LOH area. These findings suggest that MARK4L up-
regulation in glioma is caused by mechanisms other
than copy number alterations. In contrast to MARK1,
MARK2 and MARK3, which exhibit uniform cyto-
plasmic localisation, exogenous MARK4 associates
with microtubules, centrosomes, and neurite-like pro-
cesses of neuroblastoma cell lines, attesting to its
involvement in microtubule organization in neuronal
cells [4]. We recently investigated the subcellular
localisation of the endogenous MARK4L isoform in
glioma and showed that it displays multiple local-
isations, being found in centrosomes at all mitotic
stages, midbodies, nucleoli and their respective bio-
chemical fractions [19]. The localisation pattern of
MARK4L emerging from the above studies provides
further evidence for MARK4L influence on micro-
tubules, particularly those affecting the centrosome
and midbody.
The present study is aimed at deepening under-
standing of the potential oncogenic role of MARK4
in human glioma, the most common brain tumour in
adults. We first excluded the possibility that sequence
changes within theMARK4 gene, including those at the
alternative splice sites leading to the L isoform, could
be related to the reported up-regulation. We then traced
MARK4L and MARK4S expression profile in glioma
cell lines and tissues with different malignancy grades
and in glioblastoma-derived cancer stem cells (GBM
CSCs) by real-time PCR, immunoblotting (IB) and
immunohistochemistry (IHC). We also performed in
vivo localisation studies of MARK4S and MARK4L in
mouse and human adult and embryonic brain. Finally,
we investigated and compared the subcellular locali-
sations of MARK4 splice variants in glioma cell lines
and in normal cells. The integration of these datasets
highlighted a differential signature of the two MARK4
isoforms supporting a distinct role in the pathogenesis
of gliomas.
2. Materials and methods
2.1. Cell cultures
Primary glioma cell lines (Table 1A), obtained
from post-surgery specimens divided in non GBM
(1 pylocitic astrocytoma, 1 oligoastrocytoma, and
7 anaplastic astrocytomas) and GBM (10 glioblas-
tomas and 2 giant cell glioblastomas), as well as the
spheroid NHNPCs (Normal Human Neural Progenitor
Cells; Lonza, Walkersville, MD, USA) were grown
as described elsewhere [14, 20, 21]. The human
neural progenitor cell line ReNcellCX (Millipore,
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Table 1A
Set of 21 investigated primary glioma cell lines
Cell line Sex/Age at surgery WHO diagnosis/grade
G-91 M/4 PA/I
G-157 M/31 OA/II
G-110 n.a. AA/III
G-114 F/10 AA/III
G-141 n.a. AA/III
G-151 n.a. AA/III
G-6 n.a. AA/III
MI-29 F/6 AA/III
G-47 n.a. AA/III
MI-4 F/52 GBM/IV
G-32 M/63 GBM/IV
MI-38 F/73 GBM/IV
MI-45 n.a. GBM/IV
MI-51 n.a. GBM/IV
MI-60 F/36 GBM/IV
MI-63 M/45 GBM/IV
MI-70 F/66 GBM/IV
G-150 n.a. GBM/IV
GBM M/48 GBM/IV
G-1 F/62 GBM/IV
MI-7 M/51 giant cell GBM/IV
Glioma cell lines are grouped in non GBM (PA, OA, AA) and
GBM (GBM, giant cell GBM). Abbreviations: M, male; F, female;
PA, pilocytic astrocytoma; OA, oligoastrocytoma; AA, anaplastic
astrocytoma; GBM, glioblastoma; n.a., not available.
Billerica, MA, USA) was grown as a monolayer on
laminin (Sigma, Saint Louis, MI, USA) diluted with
DMEM/F12 medium (Millipore) to 20g/ml and was
maintained by serial passages in a defined serum-free
medium (Millipore/Chemicon) containing 20 ng/ml
epidermal growth factor (EGF) (Sigma) and 20 ng/ml
fibroblast growth factor-2 (FGF-2) (Invitrogen,
Camarillo, CA, USA) at 37◦C in 5% CO2. Human
adult skin fibroblasts (grown in RPMI 1640 + 10%
foetal calf serum (FBS) + 1% penicillin-streptomycin)
and human adult myoblasts (grown in DMEM + 20%
FBS + 1% penicillin-streptomycin + 2 mM L-gluta-
mine + 10g/ml insulin + 25 ng/ml FGF-2 + 10 ng/ml
EGF) were incubated in 5% CO2 at 37◦C.
Human GBM CSCs and mouse neural stem cells
(NSCs) were obtained from post-surgery specimens
of primary GBM and from the sub-ventricular zone
of post-natal 7-day-old C57 mice, respectively. GBM
CSCs were obtained through enzymatic digestion of
tumour tissues, followed by culture of the cell sus-
pension in DMEM/F12 medium without serum and in
the presence of EGF (20 ng/ml) and FGF-2 (10 ng/ml).
GBM CSCs were characterized for self-renewal, multi-
potency and tumourigenicity as described [22]. Mouse
NSCs were obtained and characterized according to
the protocol described by Foroni et al. [23].
A few GBM CSCs and NSCs were also terminally
differentiated into the three major neural cell types by
culturing them in mitogen-free medium supplemented
with 2% FBS. Immunofluorescence for neural antigens
was performed to assess differentiation [23].
2.2. Tissue samples
A total of 36 human glioma post-surgery specimens
(16 oligodendrogliomas, O; 7 astrocytomas, A; and
13 glioblastomas, GBM; Table 1B) were obtained,
in accordance with a protocol approved by the Insti-
tutional Review Board of the University of Milan’s
Neurosurgery Department, from patients with no pre-
vious chemotherapy or radiation treatment.
Human normal brain (HNB) samples included: (1)
autopsies of three stillborn infants who died after
premature delivery during the 23rd–27th gestational
week; death was not due to neurological disorders or
brain malformations, as detected by macroscopic and
microscopic examination; according to the Italian law,
autopsies were performed 24 hours after death; and
(2) brain specimens from two drug-resistant patients
operated on for intractable epilepsy; the surgery was
performed for strictly therapeutic reasons after the
patients had given their informed consent; during the
neuropathological investigation, samples did not show
any cytological alteration.
Normal rodent brain tissues were obtained from
three adult mice (C57B6/CD1), two adult rats (CD1)
and one rat embryo at embryonic day (E) 15
from Charles River Laboratories (Calco, Italy). Ani-
mals were brought up and treated in accordance
with the European Communities Council Directive
(86/609/EEC).
2.3. DNA extraction and mutation analysis
Total DNA was extracted from cell lines using the
QIAmp DNA mini kit (Qiagen, Milano, Italy) and
from tissue samples using TRI reagent (Total RNA
Isolation reagent; Sigma) according to the manufac-
turers’ protocols. Approximately 60 ng were amplified
by PCR using GoTaq polymerase (Promega, Madison,
WI, USA) and MARK4 specific primers. PCR prod-
ucts were sequenced using the Big Dye Terminator
v.3.1 Cycle Sequencing Kit and the ABI PRISM 3130
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Table 1B
Set of 36 investigated glioma biopsies: molecular and clinical characterization
Sample Sex/Age WHO diagnosis/grade Tumor site SVZ Survival/Recurrence mMGMT 1p del 19q del
4 F/52 O/II n.a. n.a. n.a. + + +
6 M/54 O/II lt − alive/− − − −
42 M/49 O/II rf − alive/+ n.e. + +
71 M/59 O/II rt − alive/− + − −
98 M/29 O/II rp − alive/− + + +
106 M/38 O/II rf − alive/+ + + +
107 F/41 O/II lf − alive/+ + + +
112 M/36 O/II rp + alive/− + + +
118 M/50 O/II lf + alive/− + + +
186 F/39 O/II rt − alive/− + + +
190 M/68 O/II lf + alive/− + + +
193 M/45 O/II rf + alive/− + + +
196 M/31 O/II rp − alive/− − − −
200 F/44 O/II lt − alive/− + + +
217 M/40 O/II lp − alive/− + + +
219 M/46 O/II rf − alive/− + + +
1 M/32 PA/II lp − alive/− + − −
41 n.a. A/II n.a. n.a. n.a. n.e. n.e. n.e.
64 M/34 PA/II lf n.a. alive/+ n.e. n.e. n.e.
94 n.a. A/II n.a. n.a. n.a. n.e. n.e. n.e.
108 F/52 AA/III lt − 32 months + − −
164 F/35 FA/II lt − alive/− − − −
216 M/34 PA/II lt n.a. alive/+ + − −
5 F/40 GBM/IV lf + 34 months − + +
21 F/72 giant cell GBM/IV f + 5 months n.e. n.e. n.e.
81 F/65 GBM/IV f + 11 months + + +
96 M/68 GBM/IV f − 18 months + n.e. n.e.
100 F/66 GBM/IV f − 12 months + + +
113 M/63 GBM/IV n.a. n.a. 15 months + − −
117 M/70 GBM/IV n.a. n.a. 16 months + − −
121 M/44 GBM/IV lt + 3 months + − −
132 M/51 GBM/IV lt + 26 months − − +
144 F/56 GBM/IV n.a. n.a. 5 months − − −
194 M/57 GBM/IV rt + alive/− − + −
207 M/64 small cell GBM/IV n.a. n.a. alive/+ − − +
218 M/58 GBM/IV rt + 14 months − + +
Abbreviations: M, male; F, female; O, oligodendroglioma; PA, pilocytic astrocytoma; A, astrocytoma; AA, anaplastic astrocytoma; FA, fibrillary
astrocytoma; GBM, glioblastoma; f, frontal; lf, left frontal; lp, left parietal; lt, left temporal; rf, right frontal; rp, right parietal; rt, right temporal;
SVZ+, tumor closeness to the sub-ventricular zone; mMGMT, O6-methylguanine–DNA methyltransferase methylation; n.a., not available; n.e.,
not evaluated.
automatic sequencer (both from Applied Biosystems,
Foster City, CA, USA). Electropherograms were anal-
ysed with ChromasPro software 1.42 (Technelysium
Pty Ltd, Tewantin QLD, Australia).
2.4. RNA isolation, reverse transcription-PCR
and real-time PCR
Total RNA was isolated from cell lines and tissues
using TRI reagent and treated with DNase I (RNase-
free, New England Bio-Labs, Inc., Ipswich, MA,
USA). RNA from total HNB (MVP Total RNA) was
also purchased from Stratagene (La Jolla, CA, USA).
cDNA was synthesized from 500 or 250 ng of total
RNA for cell lines and tissue samples, respectively,
using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) with random examers. All
samples were reverse transcribed in two independent
experiments.
The relative mRNA levels of MARK4L and
MARK4S were determined by real-time PCR using
the StepOne Real-Time PCR System (Applied
Biosystems). Isoform-specific TaqMan assays were
purchased from Applied Biosystems and used, fol-
I. Magnani et al. / Differential signature of the centrosomal MARK4 isoforms in glioma 323
lowing validation, according to the manufacturer’s
instructions. Different endogenous normalizing genes
were used, according to assay efficiency and stabil-
ity experiments previously performed: GAPDH (assay
ID: 4333764F), -actin (assay ID: Hs99999903 m1)
and 18 S rRNA (assay ID: Hs99999901 s1). Rela-
tive gene expression was determined using the Ct
method [24] or the Ct method [25].
2.5. Antibodies
Polyclonal primary antibodies for MARK4L (rabbit
anti-MARK4L; GenScript Corporation, Piscataway,
NJ, USA) and MARK4S (goat anti-MARK4S, ab5262;
Abcam, Cambridge, UK) were used. The specificity of
these antibodies was demonstrated by immunoblotting
against the over-expressed MARK4L protein and by
mass spectrometry, respectively (Supplementary Infor-
mation).
For the immunoblotting experiments anti-MARK4L
1 : 5.000, anti-MARK4S 1 : 1.250 and mouse anti-
GAPDH 1 : 10.000 (ab8245; Abcam) primary antibod-
ies were used. They were detected with horseradish
peroxidase (HRP)-conjugated secondary antibodies:
goat anti-rabbit IgG 1 : 10.000 (sc-2004), donkey anti-
goat IgG 1 : 25.000 (sc-2020) and goat anti-mouse IgG
1 : 10.000 (sc-2005) (all from Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA).
For the immunofluorescence experiments, anti-
MARK4L 1 : 100, anti-MARK4S 1 : 200, mouse
anti--tubulin 1 : 200 (clone GTU-88; Sigma), anti-
nucleolin 1 : 100 (C23 D-6; Santa Cruz Biotechnology)
and anti-nucleophosmin 1 : 200 (B23, clone FC82291;
Sigma) antibodies were used. The immunofluores-
cence signals were visualised using different secondary
antibodies: goat anti-rabbit IgG conjugated to fluo-
rescein isothiocyanate (FITC) 1 : 200 (Sigma), goat
anti-mouse IgG conjugated to tetramethylrhodamine
isothiocyanate (TRITC) 1 : 200 (Sigma), and rabbit
anti-goat IgG conjugated to Alexa 488 (Invitrogen).
Immunohistochemistry experiments on normal
brain or tumour samples were performed using the anti-
MARK4L (1 : 500/1 : 1.000) and the anti-MARK4S
(1 : 500/1 : 600) antibodies.
2.6. Protein extraction and immunoblotting
Proteins were extracted from cell lines and tis-
sue samples by lysis buffer. 20 or 25g of proteins
from each sample were resolved under reducing con-
ditions and underwent immunoblotting procedure as
described by Magnani et al. [19]. Membranes were
washed in PBS-T (100 mM NaCl, 80 mM Na2HPO4,
20 mM NaH2PO4, 0.3% Tween 20) and incubated in
5% skimmed milk in PBS-T to block non-specific bind-
ing. Primary and secondary antibodies were diluted
in PBS-T or 1% skimmed milk in PBS-T. The inten-
sity of the bands was measured using the software
ImageJ (freely available at http://rsbweb.nih.gov/ij/).
For relative semi-quantitative analysis, MARK4L pro-
tein expression was normalized on GAPDH protein
expression.
2.7. Immunoﬂuorescence
For immunofluorescence (IF) analysis, glioma and
normal cell lines were processed as described in Mag-
nani et al. [19].
GBM CSCs and NSCs were fixed as described for
the other cell lines but without prior treatment with
microtubule-stabilising buffer. For RNA degradation,
cells were permeabilised with 0.1% Triton X-100 for
5 min and treated with 800g/ml RNase A (Sigma)
and 5l RNase Cocktail (Ambion, Austin, USA) in
PBS for 30 min at room temperature (RT).
2.8. Immunohistochemistry
Human normal brain specimens were fixed in 4%
paraformaldehyde (PFA) and 0.1 M phosphate buffer
(PB; pH 7.2), embedded in paraffin and sectioned
(10m) on a microtome.
After deep anaesthesia, the animals were perfused
transcardially with 4% PFA in 0.1 M PB. Dissected
brains were post-fixed in 4% PFA for 12 hours, embed-
ded in paraffin and sectioned (10m).
All tissue sections were dewaxed in xylene, rehy-
drated, and treated in a microwave oven in 0.01 M
Na-citrate, pH 6.0. After inhibition of the endogenous
peroxidases with 1% H2O2, sections were incubated in
1% BSA (Sigma) with 0.2% Triton X-100 for 1 hour,
and then incubated overnight with primary antibod-
ies at 4◦C in a humid chamber. The antibody staining
was revealed using a biotinylated secondary antibody
diluted with 0.1% BSA in PBS. The avidin-biotin-
peroxidase protocol (ABC; Vector Labs, Burlingame,
CA, USA) was followed, using diaminobenzidine
(DAB) (Sigma) as the chromogen.
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Formalin-fixed paraffin-embedded tumour tissues
were sectioned at 3 mm onto positively charged slides
(Superfrost plus, Menzel–Glaser, Germany) and sub-
jected to heat-induced epitope retrieval with citrate at
a pH of 6.0. After inhibition of the endogenous per-
oxidases, slides were blocked for 30 min (Novolink
Polymer Detection Systems, Leica Microsystems
and Menarini Diagnostics) and incubated with
anti-MARK4L antibody overnight at 4◦C or with anti-
MARK4S antibody for 1 hour at RT. For detection,
the Novolink Polymer Detection System was used.
Immunohistochemical data from tumour tissues were
independently evaluated by two investigators.
2.9. Statistical analysis
Real-time PCR and immunoblotting experiments
were performed in triplicate for each sample; values
with standard deviations exceeding 0.5% or standard
errors exceeding 0.3% were excluded and the experi-
ments repeated. Wilcoxon signed rank, Mann-Whitney
and Kruskall Wallis tests were used to compare gene
expression data; differences between experimental
groups were considered significant when p < 0.05. All
statistical analyses were performed using StatistiXL
1.8 for Microsoft Excel (http://www.statistixl.com).
3. Results
3.1. Mutation analysis of MARK4 genomic
sequence
To determine whether mutations could affect
MARK4 activity or favour MARK4L isoform expres-
sion in gliomas [14], we sequenced both the MARK4
functionally relevant coding regions and the alterna-
tive splice sites. A subset of 12 glioma cell lines and 12
glioma tissues with different malignancy grades [26]
were tested.
We primarily screened the MARK4 kinase domain
(exons 2-10 and flanking intronic regions) and the
ubiquitin-associated (UBA) domain (exons 10–12 and
flanking intronic junctions). We also screened exon 13
as suggested by data in the literature [27]. No sequence
variations were detected in any of the investigated
samples, with the exception of a c.1101 G > C syn-
onymous substitution in exon 11 from a glioblastoma
cell line (GBM), which does not affect the splic-
ing process. To test whether mutations could affect
MARK4 genomic regions involved in exon 16 alterna-
tive splicing, favouring the production of the L isoform,
the mutational screening was extended to exons 15,
16 and 17, IVS16 and IVS17, leading to an over-
all coverage of the MARK4 coding sequence greater
than 70%. We found only a previously unreported
single nucleotide alteration within intron 16 (c.1878-
61 G > A) in 8 glioma samples. This sequence change
does not affect the splicing process, as was confirmed
by direct sequencing of the MARK4 transcript. Finally,
because the MARK4 gene is characterized by short
introns that could potentially be retained in the mature
mRNA, intron retention between exons 3-4 (152 bp),
5-6 (90 bp) and 11-12 (91 bp) was tested by PCR (and
occasionally by direct sequencing) of cDNA, but no
splicing errors were detected.
The lack of MARK4 sequence alterations and tar-
geted genomic rearrangements [18] prompted us to
evaluate the MARK4L and S expression profile by
real-time PCR, immunoblotting and immunohisto-
chemistry, in order to investigate the post-trascriptional
regulation of the MARK4 isoforms in the set of 21
glioma cell lines and 36 glioma biopsies, grouped for
WHO diagnosis and grade as reported in Tables 1A
and B.
3.2. Imbalance between MARK4L and MARK4S
transcripts in glioma cell lines and tissues
MARK4 transcripts were quantitatively evaluated
in the panels of primary glioma cell lines and glioma
tissue samples by real-time PCR.
The results from the glioma cell lines (Figs. 1A and
B) indicated that, despite considerable heterogeneity
among samples, MARK4L is the prevalent isoform and
is over-expressed in 16 out of 21 cell lines (75%) when
compared with NHNPCs (p = 0.03, Wilcoxon test).
In contrast to our previous mRNA data, which were
achieved using a semi-quantitative approach [14], we
found that the S isoform of MARK4 is expressed con-
currently with but at lower levels than MARK4L. We
determined that MARK4S expression is significantly
lower in both non GBM and GBM cell lines when
compared with NHNPCs (p = 0.00001, Wilcoxon test).
Real-time PCR data from tumour biopsies (Figs. 1C
and D), compared with data from HNB, confirmed
the heterogeneous expression of both MARK4 iso-
forms as well as the previously noted MARK4L
predominance. We did not find statistically signifi-
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A B
C D
Fig. 1. MARK4L and MARK4S mRNA expression levels. MARK4L (white bar) and MARK4S (black bar) mRNA expression levels in (A)
non GBM and (B) GBM cell lines compared with NHNPCs (set as 1 and represented as a horizontal grey line) and in (C) O and (D) A and
GBM tissues compared with HNB (set as 1 and represented as a horizontal grey line). Expression data from glioma cell lines were normalized to
GAPDH for both MARK4 isoforms, and relative mRNA levels were determined using the Ct method. Expression data from glioma tissues
were normalized to GAPDH and -actin and analysed by the Ct method. Data are expressed as mean ± standard deviation.
cant differences in MARK4L expression among the
three glioma subgroups, although a slight decrease
in median expression levels of MARK4L (A: 1.14;
O: 1.03; GBM: 0.85) was observed. In contrast,
MARK4S expression levels decreased in glioma sam-
ples compared with HNB (p = 0.00001, Wilcoxon test).
Specifically, grade II O had a median value of 0.35,
grade II/III A a median value of 0.11, and grade IV
GBM a median value of 0.03. Interestingly, in the astro-
cytic tumours (A and GBM) (Fig. 1D) the MARK4S
expression was inversely correlated with the tumour
grade (p = 0.04, Mann-Whitney test).
3.3. Immunodetection conﬁrms MARK4L
prevalence in glioma cell lines and tissues
The results of semi-quantitative IB on glioma cell
lines and tissues are reported in Fig. 2. Consistent
with the mRNA data, MARK4L protein was over-
expressed in most of the non GBM and GBM cell
lines compared with NHNPCs (p = 0.007, Wilcoxon
test) (Fig. 2A). In glioma tissues, MARK4L expression
was slightly decreased in GBM samples when com-
pared with A samples, although the differences among
the three glioma subgroups were not statistically sig-
nificant (median values: A: 1.20, O: 0.71, GBM: 0.40)
(Fig. 2B). A representative immunoblot of MARK4L
expression in tissue samples is shown in Fig. 2C.
The anti-MARK4S antibody non-specifically rec-
ognized too many bands in both glioma cell lines and
tissue samples (Fig. 2D). We thus performed mass
spectrometry analyses to identify the specific band cor-
responding to the MARK4S protein (Supplementary
Information). However, because of weak MARK4S
expression and the compactness of the bands, quan-
tification proved very difficult, particularly for tissue
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A
B
C D
Fig. 2. Relative MARK4L protein expression measured by immunoblotting. (A) non GBM and GBM cell lines compared with NHNPCs (set as
1 and represented as a horizontal grey line). (B) O, A and GBM tissues compared with HNB (set as 1 and represented as a horizontal grey line).
(C) Representative MARK4L immunoblot of O tissue samples (42, 112, 186, 217, 200, 196, 193). (D) Representative MARK4S immunoblot
of O tissue samples (107, 200, 217, 6, 219, 112). The membrane was cut (black lines) after the blocking step and incubated with the appropriate
antibodies. M, molecular weight ladders (kDa).
samples. Nevertheless, the IB results were sufficiently
reliable to confirm the MARK4S expression profile
obtained by real-time PCR (data not shown).
In vivo IHC on matched paraffin-embedded sec-
tions was performed to evaluate the expression levels
and the intra-tumour cell localisation of MARK4L and
MARK4S. The results confirmed that both the L and
S isoforms of MARK4 are heterogeneously expressed
among and within tumours and that MARK4L is the
prevalent isoform with the highest composite scores
(Table 2). All of the samples, with the exception of
GBM 144, were labelled by the anti-MARK4L anti-
body; MARK4S was instead undetectable in 7 out of
32 analysed cases (22%). Specifically, 2 out of 15 O
samples (71 and 106) (Table 2 and Fig. 1C) and 5
out of 13 GBM samples (5, 100, 132, 194 and 207)
(Table 2 and Fig. 1D) were negative for MARK4S.
Moreover, IHC showed that MARK4L had both a per-
inuclear and nuclear localisation in nearly all of the
processed tumours, in addition to a nucleolar locali-
sation in several tumour cells (Fig. 3A). In contrast,
MARK4S was mainly localised to the perinuclear
region of tumour cells (Fig. 3B). Both MARK4S and
MARK4L antibodies also labelled some differentiated
neurons, in particular pyramidal neurons, entrapped
in the tumour mass (Figs. 3A and B), whereas only
MARK4L detected endothelial cells (Fig. 3A).
3.4. A high MARK4L/MARK4S ratio tags the
undifferentiated phenotype of GBM, GBM
CSCs and NSCs
We further analyzed the MARK4L and S expression
levels in a set of GBM CSCs, which are known to repro-
duce the genotypic and phenotypic features of glial
tumours [22, 29], compared with astrocytic tumours
(A and GBM). Real-time PCR data (Fig. 4A) showed
that MARK4L is the predominant isoform. Interest-
ingly, MARK4S expression is inversely correlated with
both glioma malignancy and with the undifferentiated
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Table 2
MARK4 L and MARK4 S immunohistochemical data
MARK4L MARK4S
Sample WHO Diagnosis/ Staining Labelling Composite Staining Labelling Composite
Grade intensity extent score intensity extent score
4 O/II 2 2 4 1 2 2
6 O/II 3 3 9 n.e. n.e. n.e.
42 O/II 3 3 9 1 1 1
71 O/II 3 2 6 neg neg
98 O/II 2 3 6 1 2 2
106 O/II 3 2 6 neg neg
107 O/II 2 2 4 3 2 6
112 O/II 2 2 4 2 2 4
118 O/II 2 1 2 1 1 1
186 O/II 3 1 3 1 1 1
190 O/II 2 2 4 1 2 2
193 O/II 3 1 3 2 2 4
196 O/II 3 2 6 3 2 6
200 O/II 2 1 2 1 1 1
217 O/II 1 2 2 1 2 1
219 O/II 2 2 4 2 2 4
1 PA/II 3 3 9 2 3 6
41 A/II n.e. n.e. n.e. n.e. n.e. n.e.
64 PA/II 3 2 6 n.e. n.e. n.e.
94 A/II n.e. n.e. n.e. n.e. n.e. n.e.
108 AA/III 3 1 3 1 1 1
164 FA/II 2 1 2 1 1 1
216 PA/II 3 2 6 2 2 4
5 GBM/IV 2 3 6 neg neg
21 giant cell GBM/IV 2 3 6 2 2 4
81 GBM/IV 2 2 4 1 2 2
96 GBM/IV 1 1 1 1 1 1
100 GBM/IV 3 3 9 neg neg
113 GBM/IV 2 2 4 1 1 1
117 GBM/IV 2 1 2 neg neg
121 GBM/IV 2 2 4 1 1 1
132 GBM/IV 3 1 3 neg neg
144 GBM/IV neg neg 2 2 4
194 GBM/IV 1 1 1 neg neg
207 small cell GBM/IV 1 2 2 1 1 1
218 GBM/IV 1 2 2 2 2 4
The staining intensity of a minimum 100 cells from each specimen was visually graded on a scale ranging from 0 to 3 (0 = no staining; 1 = weak,
2 = moderate, and 3 = strong staining). The extent of labelling was scored on the basis of the percentage of immunopositive cells: 0 ≤ 5%;
1 = 6–35%; 2 = 36–66% and 3 ≥ 67%. A composite score was then obtained by multiplication of the intensity and extent scores as described in
Chauhan et al. [28]. Abbreviations: O, oligodendroglioma; PA, pilocytic astrocytoma; A, astrocytoma; AA, anaplastic astrocytoma; FA, fibrillary
astrocytoma; GBM, glioblastoma; neg, negative; n.e. not evaluated.
phenotype of tumour cells (p = 0.001, Kruskal–Wallis
test). As a result of this significant decrease in
MARK4S expression, the MARK4L/MARK4S ratio
increases progressively (Fig. 4B).
GBM CSCs compared with mouse postnatal NSCs,
the most likely glioma cells-of-origin, showed slightly
higher levels of MARK4L, while MARK4S was hardly
detectable in both stem cell groups (Fig. 4C).
We also evaluated the MARK4L expression profile
in terminally differentiated NSCs and GBM CSCs by
IB. We found that both differentiated and undifferen-
tiated GBM CSCs shared similar MARK4L protein
levels, whereas in NSCs the L isoform became unde-
tectable by the 7th day of differentiation (Fig. 4D). The
MARK4S expression profile in GBM CSCs and NSCs
was not determined by IB because of the difficulty in
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Fig. 3. Representative images of MARK4 immunohistochemistry experiments in glioma tissues. (A) MARK4L and (B) MARK4S labelling of
O (samples 193 and 196) and GBM (samples 207 and 113). Arrows indicate neurons entrapped in the tumor mass labelled by both MARK4
antibodies. Double arrows point to endothelial cells expressing MARK4L. IHC was performed using the DAB method with haematoxylin
counterstaining.
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A B
C D
Fig. 4. MARK4 expression profile in GBM CSCs and NSCs. (A) Relative expression of MARK4L (white bar) and MARK4S (black bar)
mRNA in A, GBM and GBM CSCs compared with HNB (set as 1 and represented as a horizontal grey line). Data were normalized to GAPDH
and -actin and analyzed by the Ct method. (B) MARK4L/MARK4S mRNA ratio in A, GBM and GBM CSCs. (C) MARK4L (white bar)
and MARK4S (black bar) transcript levels in GBM CSCs and mouse NSCs compared with HNB (set as 1). Data were analyzed with the
Ct method using 18 S rRNA as the endogenous control. Real-time data are expressed as mean ± standard deviation. (D) Immunoblotting for
MARK4L in undifferentiated and differentiated GBM CSCs (070104, 0627) and NSCs. The membrane was cut (black line) after the blocking
step and incubated with the appropriate antibodies. M, molecular weight ladders (kDa).
identifying the specific band due to the low level of
MARK4S expression.
3.5. The alternative MARK4L isoform is
expressed in normal brain ventricular
and sub-ventricular zones
We investigated MARK4L and MARK4S expres-
sion in both human and rodent tissues from adult and
embryonic brain by IHC. The overall distribution of
the two MARK4 isoforms was similar in the cortical
grey and white matter, but it differed in the embry-
onic ventricular zone and adult sub-ventricular zone
(SVZ), both of which are known germinal sites in the
brain (Fig. 5). In embryos, MARK4L was expressed
in some cells located in the ventricular zone (Fig. 5A)
and in some post-mitotic neurons in the intermedi-
ate zone and in the cortical plate (data not shown).
In line with the low levels of MARK4S transcript
in cultured NSCs, the S isoform was undetectable in
the ventricular zone, although it was expressed in the
embryonic post-mitotic neurons (Figs. 5B). Interest-
ingly, MARK4L, unlike MARK4S, was expressed in
some cells of the SVZ in adult rodents (Figs. 5C and D).
In the white matter, some glial cells appeared to be
immunolabelled for MARK4L (Fig. 5E), while fewer
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Fig. 5. In vivo expression of MARK4L and MARK4S in human and mouse brain. (A) MARK4L expression in some cells of the ventricular zone
in the human embryo (arrows) and (B) lack of MARK4S expression in the same area. (C and high-magnification inset) MARK4L expression
in some cells of the SVZ in the adult mouse brain and (D and high-magnification inset) lack of MARK4S expression in the same area. (E and
G) MARK4L and (F and H) MARK4S are expressed in some glial cells (arrows) in the white matter of the adult human cerebral cortex. Both
proteins are also expressed in several neurons (arrowheads in G and H) and in some glial cells (arrows in G and H) in the gray matter. V, ventricle;
SVZ, sub-ventricular zone; WM, white matter. Scale bar = 14.5m in A, B and in insets in C, D; 74m in C–H; 44.4m in insets in E, F.
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cells were MARK4S-positive (Fig. 5F). In the cere-
bral cortex, both MARK4L and MARK4S antibodies
detected a few glial cells and most of the neurons
distributed throughout the cortical layers (Figs. 5G
and H).
3.6. The MARK4L isoform is delineated as a
tumour marker through nucleolar association
New evidence illuminating the role of MARK4 iso-
forms has been provided by IF studies. We demonstrate
herein that MARK4S localises to the centrosome and
midbody in glioma cell lines (Fig. 6A), as has been pre-
viously shown for MARK4L [19]. However, in contrast
to the L isoform, no immunoreactivity with nucleolar
structures was observed for MARK4S in glioma cell
lines (Fig. 6B). IF experiments on normal cells, includ-
ing human neural progenitors (ReNcellCX), adult
fibroblasts and myoblasts, showed that both MARK4
isoforms are undetectable in the nucleoli (Figs. 6C–E),
but are associated to the centrosome and midbody as in
glioma cell lines (Figs. 6F–H). Furthermore, we inves-
tigated the MARK4L nucleolar localisation in GBM
CSCs, NSCs and their differentiated counterparts. We
performed double-IF with anti-MARK4L and anti-
nucleolin antibodies and found a specific nucleolar
association of MARK4L in 2 out of 3 GBM CSC sam-
ples. We also found that the MARK4L nucleolar signal
is stronger in differentiated cells than in their undiffer-
entiated progeny (Figs. 6I and J). In contrast, MARK4L
was never detectable in the nucleoli of NSCs (Figs. 6K
and L). Hence, the nucleolar association appears to be
a specific feature of the L isoform of MARK4 and is
detectable only in glioma cells.
We also determined by IF that RNase treatment of
fixed MI-4 GBM cells abolishes the nucleolar locali-
sation of both MARK4L and nucleophosmin (NPM),
suggesting that MARK4L may be physically asso-
ciated with nucleolar RNAs or ribonucleoproteins
(Figs. 6M and N). In contrast, the midbody localisa-
tion of MARK4L was maintained in RNase treated
cells (Fig. 6M).
4. Discussion
We previously reported that the up-regulation of
MARK4L noticed in glioma cannot be explained by
copy-number variations [18]. Our sequence analysis
of MARK4, intended to disclose whether the enhanced
kinase expression is set in motion by mutations, failed
to reveal any alteration. Accordingly, in 91 GBM
samples analysed for 518 protein kinase genes by
the Cancer Genome Atlas [27], only a splice-site
mutation in exon 13 affected MARK4. Other muta-
tions hitting exons 5, 8, 9 and 12 have been found
in different tumours [30], although their role in the
tumour process has not been dissected. We therefore
postulated that other mechanisms, acting at the post-
transcriptional level, may favour MARK4L expression
to the detriment of MARK4S, likely conferring a
selective advantage during tumour development and
progression. In line with previous data, this study reaf-
firms that the L splice variant is the over-expressed
isoform of MARK4 in glioma cell lines and is the more
abundant isoform in a wide panel of tumours of differ-
ent malignancy grades (Tables 1A and B). The slight
discrepancy in transcript and protein levels observed
between tissues and cell lines is consistent with the
known tumour heterogeneity and the remarkable phe-
notypic diversity of glial tumours [31]. The highly
variable expression of MARK4 in different samples
may indeed reflect differences in their glioma-initiating
cells [32]. Real-time PCR analyses highlighted that
both L and S isoforms of MARK4 are concurrently
expressed in glioma cell lines and tissues. However,
unlike the L isoform, MARK4S transcript levels show
a significant decrease that is correlated with tumour
malignancy. This decrease is evidence of a switch
towards MARK4L expression and an associated loss of
differentiation (Figs. 1C–D and 4A). A likely hypoth-
esis is that the balance between the MARK4 isoforms
is carefully guarded during the normal differentia-
tion program in neural tissue but may be subverted
in gliomagenesis. In this context, MARK4 alternative
splicing appears to be the most likely mechanism regu-
lating MARK4L and S balance and may be a molecular
target of tumour transformation in gliomas [33]. Of
the many consequences of alternative splicing in the
central nervous system (CNS), a few are reported to
underlie both simple and complex diseases, includ-
ing cancer [34]. A relevant example is provided by
taupathies, where the altered ratio of the alternative
splicing-derived Tau isoforms, 3R-tau and 4R-tau, is
sufficient to cause neurodegeneration and dementia
[35]. Interestingly, Tau is a downstream element in
the MARK4 protein pathway [4]. In cancer, aberrant
splicing events have been implicated in the failure of a
class of molecules whose normal function is to control
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Fig. 6. Representative immunofluorescence images of MARK4L and MARK4S.
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the balance between cell proliferation and differentia-
tion in stem cells and during embryonic development
[32, 36]. Examples include the nerve growth factor
TrkAIII variant, which is found in both neural stem
cells and neuroblastoma [37], and the caspase 8 L,
which is expressed in both hematopoietic stem cells
and leukaemias [38]. Brain tumours have also been
reported to retain a foetal variant of the neurofibro-
matosis gene NF1 [39], and foetal forms of the insulin
receptor and fibronectin are also maintained in various
cancers [40]. Accordingly, we found that MARK4L
expression levels are consistently predominant in both
GBM CSCs and NSCs, whereas MARK4S expression
faded in both cases (Fig. 4C). Notably, under differ-
entiation conditions, while MARK4L expression is
switched off in post-mitotic NSC progeny, it is main-
tained in GBM CSCs (Fig. 4D). This behaviour is
reminiscent of that of other brain stem cell markers
such as CD133 and nestin during differentiation assays
[41, 42]. This evidence, in addition to the in vivo local-
isation of the sole MARK4L isoform in a subset of
adult and embryonic ventricular/sub-ventricular zone
cells (Figs. 5A–D), not stained by MARK4S, sug-
gests that this MARK4 expression profile is part of
a stemness-expression program which may be main-
tained by glioma cells. Therefore, we may hypothesize
that a few of the GBMs in our panel may have orig-
inated from transformed neural stem cells, as they
express almost exclusively MARK4L and show a close
spatial relationship with the SVZ by magnetic reso-
nance imaging on the carrier patients (Table 1B). In
addition, the in vivo detection of both MARK4L and S
in few glial cells and human neurons (Figs. 5E–H and
arrows in Fig. 3) associates MARK4S expression with
neural differentiation, extending our published data on
mouse CNS [12].
It has recently been pointed out that alternative
splicing products that are involved in the maintenance
of chromosome segregation fidelity can contribute
to chromosomal instability (CIN) [43]. These tran-
scriptional variants are often over-expressed, causing
multipolar mitoses and mis-segregation in cancer cell
lines and tissues. The MAD1ß and Aurora B isoforms
provide excellent examples [44, 45]; these isoforms
lead first to errors in the mitotic spindle checkpoint
and ultimately to CIN. Centrosome abnormalities are
also caused by an imbalance in splice variants of pro-
teins that are key centrosome regulators, like TrkAIII,
which is over-expressed in advanced neuroblastoma
and primary glioblastoma [46], and NEK2A [47],
which has been proposed as a tumour marker and is
abnormally expressed in most cancer cell lines and
tumours. In keeping with this evidence, we have pre-
viously shown a connection between the alternatively
spliced MARK4L isoform and aberrant centrosomes
in glioma cell lines by co-immunofluorescence exper-
iments with anti-MARK4L and -tubulin antibodies,
suggesting that there is a link between the alternatively
spliced kinase and the mitotic instability frequently
observed in human glioma [19]. In a continued effort
to dissect the similar, complementary or antagonistic
properties of MARK4L and S in glioma, the present
study demonstrates that both MARK4 isoforms are
localised to the centrosome and midbody in both
glioma cell lines and various normal cells, includ-
ing neural progenitors (Figs. 6A and F–H). Thus, the
presence of MARK4 protein in these compartments
is neither isoform- nor tumour-specific and suggests
that the main function of the kinase impacts centro-
some and midbody activity. Like the other members of
the MARK family, MARK4 is a key regulator of the
dynamics of microtubules, including the mitotic spin-
dle microtubules nucleated by centrosomes. MARK4
also participates in the depolymerisation of micro-
tubules during anaphase by phosphorylating MAPs,
many of which have been identified in the mitotic spin-
(Fig. 6 continued). (A) Double MARK4S (green) and -tubulin (red) immunostaining of the MI-60 cell line showing the colocalisation of
the kinase with the midbody (yellow arrow) and centrosomes (white arrow) near the nucleus. (B) In G-91 cells, MARK4S does not exhibit
colocalisation with the nucleoli, identified by the nucleolin red signals. (C–E) Co-labelling of both MARK4 isoforms (green) and nucleolin
(red) in normal cells. (C) MARK4S does not colocalise with the nucleoli in ReNcellCX. MARK4L does not localise to the nucleoli of (D)
adult fibroblasts or (E) myoblasts. (F) MARK4S and (G–H) MARK4L (green) colocalise with -tubulin (red) in the midbody and centrosomes
of matched normal cells. (I–L) Representative images of MARK4L immunofluorescence in human GBM CSCs and mouse NSCs. Double-
immunostaining of MARK4L (green) and nucleolin (red) in GBM CSCs shows (I) strong MARK4L signals in the differentiated progeny and
(J) a faint labelling of the kinase in the nucleoli of undifferentiated GBM CSCs. (K and L) MARK4L is not detectable in the nucleoli of either
differentiated or undifferentiated mouse NSCs. (M and N) Effect of RNase treatment on MARK4L and nucleophosmin (NPM) sub-cellular
localisation in the MI-4 GBM cell line. (M) Absence of both MARK4L (green) and NPM (red) fluorescent signals in the nucleoli of RNase
treated cells, while MARK4L midbody association is maintained. (N) Both MARK4L and NPM localise to the nucleoli of RNase-untreated
cells. Nuclei are counterstained with DAPI. Magnification = 63×.
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dle [48]. In addition to this main function, most likely
shared by the two MARK4 isoforms, the association of
only the MARK4L isoform to nucleoli in glioma and
in both differentiated and undifferentiated GBM CSCs
(Figs. 6B–L) suggests that in tumours the L variant
has isoform-specific functions and interactions with
nucleolar components. This hypothesis is preliminarily
supported by experiments showing MARK4L deple-
tion in the nucleoli following treatment with RNase
(Figs. 6M and N). In keeping with the general view that
the nucleolar localisation would result from retention
rather than targeting to this compartment [49], the anal-
ysis of whole-proteome predicted nuclear/nucleolar
localisation signals (NLS/NoLS) has not revealed any
of these consensus sequences in MARK4 kinase. It
is worth noting that MARK4 activity is regulated by
post-translational modifications, such as phosphoryla-
tion and ubiquitinylation, that take place also in the
nucleolus, suggesting that MARK4L specific nucleo-
lar localisation in tumours may account not only for
the MARK4L and S expression profiles but also for
possible differences in their activation patterns.
5. Conclusions
In conclusion, these data provide evidence on dis-
ruption of the MARK4L/MARK4S balance in gliomas,
which is particularly striking in GBM and GBM CSCs.
Moreover, the in vivo localisation of the sole MARK4L
isoform in the brain ventricular zone enriched in stem
cells suggests that this MARK4 expression profile is
part of a stemness-expression program which may
be maintained by glioma cells. The altered ratio of
MARK4 isoforms in glioma may favour the pres-
ence of MARK4L to the nucleoli, an exclusive feature
of cancer cells. Ongoing experiments investigating
the significance of MARK4 sub-cellular localisation
in glioma by isoform-specific over-expression and
siRNA-mediated depletion will allow us to understand
the intricate coupling of the two isoforms. Further stud-
ies are needed to comprehend MARK4 activation state
and to define the mechanisms underlying the altered
MARK4 alternative splicing in glioma.
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Supplementary information
1. GenScript customised anti-MARK4L
antibody validation
Full-length MARK4L cDNA was amplified by PCR
from the total cDNA of the ReNcellCX cell line
using Pfu DNA polymerase (Promega) and MARK4L-
specific primers also harbouring BamHI and EcoRI
restriction sites. MARK4L cDNA was then digested,
purified and cloned into the BamHI/EcoRI site of
the mammalian expression vector pcDNA4/HisMax
(Invitrogen). This vector includes a cleavable N-
terminal Xpress™ tag for the detection of the
recombinant protein with mouse anti-Xpress™ anti-
body (1 : 5.000). Direct sequencing confirmed that
MARK4L cDNA was properly orientated, in frame
with the fusion tag and without sequence variations.
HEK293T cells were cultured in DMEM supple-
mented with 10% FBS and 1% penicillin-streptomycin
at 37◦C in a 5% CO2 atmosphere. Cells were seeded
on a 6-cm plate and transfected at approximately 30%
confluence by calcium-phosphate precipitation, using
6.5g of plasmid DNA mixed with 22l of 2 M CaCl2
and 180l of 2X HEPES-buffered saline (HBS) in a
final volume of 500l. This solution was incubated
for 30 min at RT and then added to the cells in culture.
The medium was removed 24 hours after transfection
and cells were incubated with fresh complete medium
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Supplementary Figure 1. Anti-MARK4L antibody validation. Both
the anti-MARK4L and anti-Xpress antibodies recognise the over-
expressed MARK4L protein in immunoblotting experiments.
HEK293T cells were transfected with plasmid DNA encoding the
fusion protein MARK4L + Xpress tag. The anti-MARK4L antibody
stains the endogenous MARK4L protein (lower band) and the fusion
protein (upper band), whose higher molecular weight is due to the
Xpress tag and the histidine tail. The membrane was cut (black lines)
after the blocking step and incubated with the appropriate antibod-
ies. NT, non-transfected HEK293T cells; T, transfected HEK293T
cells; M, molecular weight ladders (kDa).
for 24 hours prior to protein extraction. By perform-
ing immunoblotting experiments on proteins from the
transfected HEK293T cells, we determined that both
the anti-XpressTM and the GenScript anti-MARK4L
antibodies recognized the over-expressed MARK4L
protein (Suppl. Fig. 1).
2. Abcam anti-MARK4S antibody validation
Lysates (containing 1 mg of proteins) from a
representative glioma cell line and a tissue sam-
ple were subjected to direct immunoprecipitation.
PureProteomeTM Protein G Magnetic Beads (100l;
Millipore) were incubated, following the manufac-
turer’s instruction, with 10g of anti-MARK4S
antibody for 1 hour at RT with agitation. The lysate was
then added to the immobilized antibody and incubated
at 4◦C ON with continuous mixing. After five washes
in 0.5 ml PBS containing 0.5% Tween 20, the immuno-
precipitated proteins were eluted in non-reducing SDS
loading buffer (Cell Signaling Technology) by denatur-
ing at 90◦C for 10 min and subjected to SDS-PAGE,
together with the corresponding whole cell lysates, as
described [19].
Following electrophoresis, gels underwent both
the immunoblotting procedure, described above, and
mass-compatible silver staining.
For mass spectrometry identification, each band
positively detected by immunoblotting analysis was
excised, destained with 50% acetonitrile in 0.1 M
ammonium bicarbonate (40 min at 25◦C), dried in
a Speed Vac, soaked with 0.1 M ammonium bicar-
bonate, reduced, derivatised with 2-iodoacetamide
and digested ON at 37◦C with sequencing-grade
trypsin (Roche, Monza, Italy). The in-gel tryptic digest
was extracted with 50% acetonitrile in 0.1% trifluo-
roacetic acid (TFA). Digested aliquots were removed
and subjected to a desalting/concentration step on a
ZipTipC18 (Millipore) using 40% CH3CN in 0.1%
TFA as the eluent before LC-ESI-MS/MS analysis
using a Dionex UltiMate 3 000 HPLC System (Dionex
S.p.A, San Donato Milanese, Italy) with a Hypersil
Gold column (150 mm, internal diameter of 180m
filled with 3m Reprosil-Pur C18-AQ resin - Dr.
Maisch GmbH, Ammerbuch-Entringen, Germany).
The gradient consisted of 5–15% acetonitrile in 0.1%
formic acid for 10 min, 15–40% acetonitrile in 0.1%
formic acid for 52 min and 40–95% acetonitrile in
0.1% formic for 68 min at a flow rate of 1.2l/min.
The eluate was electrosprayed into an LTQ Orbitrap
Velos (Thermo Fisher Scientific, Bremen, Germany)
through a Proxeon nanoelectrospray ion source. The
LTQ Orbitrap Velos was operated in a CID top 5 mode.
The resolution was 60.000 (m/z 400) for the Orbi-
trap, whereas fragment spectra were read out at low
resolution in the LTQ. Ion trap and Orbitrap maxi-
mal injection times were set to 50 ms and 1000 ms,
respectively. The ion target values were 5.000 for the
ion trap and 1.000.000 for the Orbitrap. Raw files
were processed using version 1.1 of Protein Discoverer
(Thermo Fisher Scientific). For protein identification,
the SEQUEST program was used to search the NCBI
Protein Data Bank with carbamidomethylation set as
a fixed modification and oxidation (Met), phosphory-
lation (Ser, Thr and Tyr) and deamidation (Asn and
Gln) set as variable modifications. Initial peptide mass
tolerance was set to 10 ppm and fragment mass tol-
erance was set to 0.8 Da. Two missed cleavages were
allowed. Peptide quality scores were derived by pro-
cessing against decoy shuffled databases.
Supplementary Figure 2 shows the mass spectrome-
try results from MI-4 whole cell lysate and reports the
336 I. Magnani et al. / Differential signature of the centrosomal MARK4 isoforms in glioma
kDa M       MI4                  MI4
140
100
80
60
50
40
a b c
Sequences of MARK4S peptides
42CRNSIASCPEEQPHVGNYR60
350ESLTSQKYNEVTATYLLLGR370
389APSDTTNGTSSSK401
640CVSGASLPQGSK651
660ESGDLRSQVAIYLGIK674
665SQVAIYLGIKR675
Supplementary Figure 2. Mass spectrometric identification of the
band corresponding to MARK4S protein in MI-4 whole cell lysate.
(A) Arrows indicate the band, detected by the anti-MARK4S anti-
body from Abcam, corresponding to MARK4S protein. (B) The
matching silver-stained band was excised and analysed by mass
spectrometry. (C) Sequences of MARK4S peptides found in the
indicated band; the first three sequences are shared by both MARK4
isoforms (amino acids 1–625), whereas the last three are specific to
the S isoform (amino acids 626-688). M, molecular weight ladders
(kDa).
Supplementary Figure 3. The anti-MARK4S antibody does not
recognize the over-expressed MARK4L protein. HEK293T cells
were transfected with plasmid DNA encoding the fusion protein
MARK4L + Xpress tag (lane T). The anti-MARK4L antibody (right)
stains the endogenous MARK4L protein (lower band) and the
over-expressed fusion protein (upper band). Signals from the anti-
MARK4S antibody (left) are present only in the MI-4 lane, whereas
in HEK293T cells, there is no evidence of MARK4S expression.
Significantly, the anti-MARK4S antibody does not stain the over-
expressed MARK4L protein in transfected HEK293T cells. The
membrane was cut (black line) after the blocking step and incu-
bated with the appropriate antibodies. MI-4, glioblastoma cell line;
T, transfected HEK293T cells; NT, non-transfected HEK293T cells;
M, molecular weight ladders (kDa).
sequences of the peptides that allowed the unequivo-
cal identification of the band indicated by the arrow as
the MARK4S isoform. Data were also confirmed on
immunoprecipitated samples (not shown).
In addition, we verified that the anti-MARK4S anti-
body did not recognize the L protein (Supplementary
Figure 3).
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